ASCO Updates Breast Cancer Follow
The American Society of Clinical Oncology (ASCO) has updated its guidelines for breast cancer follow-up, moving toward a risk-stratified approach. This new framework aims to tailor surveillance intensity based on individual patient risk rather than a one-size-fits-all model.
Why it matters
This shift addresses the need for more efficient healthcare resource allocation while acknowledging the current lack of high-quality evidence for uniform surveillance.
The American Society of Clinical Oncology has released an updated guideline on breast cancer follow-up and surveillance after primary treatment, introducing a more risk-adapted approach to post-treatment care for patients who have completed curative-intent therapy and have no clinical evidence of disease.
The guideline update, accepted for publication in the Journal of Clinical Oncology, was developed by an ASCO Expert Panel led by Zeina Nahleh, MD, and Maryam Lustberg, MD, MPH. It provides recommendations for follow-up intensity, mammography, blood-based biomarkers, and supplemental imaging after primary breast cancer treatment.
For decades, breast cancer follow-up has often followed a relatively uniform structure: regular clinical visits, annual mammography when breast tissue remains, and symptom-directed evaluation when needed.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in